Treating HCV infection in children
Christine K. Lee, Maureen M. Jonas – 4 March 2015 – Watch a video presentation of this article
Single‐incision laparoscopic cholecystectomy
Andres Castellanos, Jessica Fazendin, Lucian Panait – 4 March 2015 – Watch a video presentation of this article
Access to new direct‐acting antiviral agents against HCV infection: A view from Spain
Santiago Tomé, Esteban Otero – 4 March 2015 – Watch a video presentation of this article
New treatments for HCV: Perspective from Asia
Ming‐Lung Yu, Wan‐Long Chuang – 4 March 2015 – Watch a video presentation of this article
Successful liver transplantation in a child with acute‐on‐chronic liver failure and acquired thrombotic thrombocytopenic purpura
Delphine Arni, Fabienne Gumy‐Pause, Marc Ansari, Johanna A. Kremer Hovinga, Valérie A. McLin – 27 February 2015
Adaptation of the hepatitis B virus core protein to CD8+ T‐cell selection pressure
Helenie Kefalakes, Bettina Budeus, Andreas Walker, Christoph Jochum, Gudrun Hilgard, Andreas Heinold, Falko M. Heinemann, Guido Gerken, Daniel Hoffmann, Joerg Timm – 26 February 2015 – Activation of hepatitis B virus (HBV)–specific CD8 T cells by therapeutic vaccination may promote sustained control of viral replication by clearance of covalently closed circular DNA from infected hepatocytes. However, little is known about the exact targets of the CD8 T‐cell response and whether HBV reproducibly evades CD8 T‐cell immune pressure by mutation.
Risk scores for hepatocellular carcinoma in chronic hepatitis B
Morris Sherman, Ray W. Kim, James Dziura – 26 February 2015
Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause‐specific outcomes
Hamish A. Innes, Scott A. McDonald, John F. Dillon, Sam Allen, Peter C. Hayes, David Goldberg, Peter R. Mills, Stephen T. Barclay, David Wilks, Heather Valerio, Ray Fox, Diptendu Bhattacharyya, Nicholas Kennedy, Judith Morris, Andrew Fraser, Adrian J. Stanley, Peter Bramley, Sharon J. Hutchinson – 26 February 2015 – Sustained viral response (SVR) is the optimal outcome of hepatitis C virus (HCV) therapy, yet more detailed data are required to confirm its clinical value. Individuals receiving treatment in 1996‐2011 were identified using the Scottish HCV clinical database.
Reply
Zheng Zhang, Jian‐Gao Fan, Fu‐Sheng Wang – 26 February 2015
Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4‐phenylbutyrate
Emmanuel Gonzales, Brigitte Grosse, Brice Schuller, Anne Davit‐Spraul, Filomena Conti, Catherine Guettier, Doris Cassio, Emmanuel Jacquemin – 26 February 2015 – Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a result of mutations in ABCB11 encoding bile salt export pump (BSEP), the canalicular bile salt export pump of hepatocyte. In some PFIC2 patients with missense mutations, BSEP is not detected at the canaliculus owing to mistrafficking of BSEP mutants. In vitro, chaperone drugs, such as 4‐phenylbutyrate (4‐PB), have been shown to partially correct mistrafficking.